AlloMap gene expression profiling is used by over 90% of US transplant centers, and since approval has been used over 150,000 times in nearly 30,000 patients.
New ISHLT Guidelines Support Use of CareDx’s HeartCare Solutions, AlloMap and AlloSure, in Routine Monitoring of Heart Transplant Patients – Read More
AlloMap gene expression profiling is used by over 90% of US transplant centers, and since approval has been used over 150,000 times in nearly 30,000 patients.
HeartCare provides a comprehensive assessment of graft rejection by combining AlloMap Heart gene expression profiling with AlloSure® Heart dd-cfDNA
CareDx is continuing to innovate with new products and post-market approval studies